Bhatla Neerja, Nene Bhagwan M, Joshi Smita, Esmy Pulikottil O, Poli Usha Rani Reddy, Joshi Geeta, Verma Yogesh, Zomawia Eric, Pimple Sharmila, Prabhu Priya R, Basu Partha, Muwonge Richard, Hingmire Sanjay, Sauvaget Catherine, Lucas Eric, Pawlita Michael, Gheit Tarik, Jayant Kasturi, Malvi Sylla G, Siddiqi Maqsood, Michel Angelika, Butt Julia, Sankaran Subha, Kannan Thiraviam Pillai Rameshwari Ammal, Varghese Rintu, Divate Uma, Willhauck-Fleckenstein Martina, Waterboer Tim, Müller Martin, Sehr Peter, Kriplani Alka, Mishra Gauravi, Jadhav Radhika, Thorat Ranjit, Tommasino Massimo, Pillai M Radhakrishna, Sankaranarayanan Rengaswamy
Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi 110029, India.
Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi District, Solapur, Maharashtra 413401, India.
Papillomavirus Res. 2018 Jun;5:163-171. doi: 10.1016/j.pvr.2018.03.008. Epub 2018 Mar 22.
Extending two-dose recommendations of HPV vaccine to girls between 15 and 18 years will reduce program cost and improve compliance. Immunogenicity and vaccine targeted HPV infection outcomes were compared between 1795 girls aged 15-18 years receiving two (1-180 days) and 1515 girls of same age receiving three (1-60-180 days) doses. Immunogenicity outcomes in 15-18 year old two-dose recipients were also compared with the 10-14 year old three-dose (N = 2833) and two-dose (N = 3184) recipients. The 15-18 year old two-dose recipients had non-inferior L1-binding antibody titres at seven months against vaccine-targeted HPV types compared to three-dose recipients at 15-18 years and three-dose recipients at 10-14 years of age. Neutralizing antibody titres at 18 months in 15-18 year old two-dose recipients were non-inferior to same age three-dose recipients for all except HPV 18. The titres were inferior to those in the 10-14 year old three-dose recipients for all targeted types. Frequency of incident infections from vaccine-targeted HPV types in the 15-18 year old two-dose recipients was similar to the three dose recipients. None of the girls receiving two or three doses had persistent infection from vaccine-targeted types. These findings support that two doses of HPV vaccine can be extended to girls aged 15-18 years.
将人乳头瘤病毒（HPV）疫苗两剂接种方案扩展至15至18岁的女孩将降低项目成本并提高依从性。比较了1795名15 - 18岁接种两剂（第1剂和第180天）的女孩与1515名同年龄接种三剂（第1剂、第60天和第180天）的女孩的免疫原性及疫苗靶向HPV感染结果。还将15 - 18岁两剂接种者的免疫原性结果与10 - 14岁接种三剂（N = 2833）和两剂（N = 3184）的接种者进行了比较。与15 - 18岁的三剂接种者及10 - 14岁的三剂接种者相比，15 - 18岁的两剂接种者在七个月时针对疫苗靶向HPV类型的L1结合抗体滴度非劣效。除HPV 18外，15 - 18岁两剂接种者在18个月时的中和抗体滴度对于所有靶向类型均不低于同年龄的三剂接种者。对于所有靶向类型，这些滴度均低于10 - 14岁三剂接种者。15 - 18岁两剂接种者中疫苗靶向HPV类型的感染发生率与三剂接种者相似。接受两剂或三剂接种的女孩均未出现疫苗靶向类型的持续感染。这些发现支持将两剂HPV疫苗接种方案扩展至15 - 18岁的女孩。
